What is Nuvectis Pharma, Inc.'s investing cash flow?

Nuvectis Pharma, Inc. (NVCT) reported investing cash flow of $0 in Q1 2026.

What does investing cash flow mean?

Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Bristol-Myers SquibbBMY

-$131M+73.7%

PfizerPFE

$785M-76.0%

Immix Biopharma, Inc.IMMX

-$4.8M-6,990%

Relmada Therapeutics, Inc.RLMD

-$135.23M-980%

Nuvation BioNUVB

-$43.64M-181%

ImmunomeIMNM

-$12.02M-336%

Operating income-$6.3M-12.4%

Net income-$6.1M-13.5%

EPS (diluted)-$0.26+3.7%

Cash & equivalents$25.1M-15.9%

Total equity$14.2M-32.1%

Total assets$25.4M-15.8%

Operating cash flow-$6.5M-56.0%

Market cap$739.27M+335%

Return on equity-154.4%+79.4pp

Current ratio2.3×-1.0×

Reported directly by Nuvectis Pharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Nuvectis Pharma, Inc.'s investing cash flow?: Nuvectis Pharma, Inc. (NVCT) reported investing cash flow of $0 in Q1 2026.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.